지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.1
- 수록면
- 588 - 593 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: To assess the efficacy and safety of docetaxel rechallenge in the salvage setting in metastatic castration-resistant prostate cancer (mCRPC) patients. Materials and Methods: Clinicopathologic data from patients treated with docetaxel rechallenge were collected from a single-center cancer registry. Among 227 patients who received first-line docetaxel for mCRPC between January 2011 and June 2019, 23 undergo rechallenge docetaxel after failure to androgen receptor targeting agents and/or cabazitaxel treatment. Endpoints included radiologic progression-free survival (PFS), treatment duration, and prostate-specific antigen (PSA) response and safety. Results: Overall, 30%, 44%, 13%, and 13% of patients received docetaxel rechallenge as either the third, fourth, fifth, or sixth-line therapy, respectively, at a median of 23.6 months after stopping first-line docetaxel. With first-line docetaxel and rechallenge, median treatment duration was 6.4 and 3.3 months, respectively. With docetaxel rechallenge, PSA response was 35% (95% confidence interval [CI], 15% to 54%) and median PFS was 4.5 months (95% CI, 1.9 to 7.1 months). The median OS was 24.3 months (95% CI, 4.6 to 44.0 months). There were 7 severe adverse events (grade 3 or more) including anemia (8.7%), neutropenia, thrombocytopenia, leukopenia, diarrhea, and nausea (4.3% each). Conclusions: Docetaxel rechallenge showed meaningful anti-tumor activity with acceptable toxicity in heavily pretreated patients with mCRPC.
목차
등록된 정보가 없습니다.
참고문헌 (14)
참고문헌 신청
정규원 / 2019 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016 / Cancer Research and Treatment 51(2):417~430
Tannock IF / 2004 / Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer / N Engl J Med 351:1502~1512
Petrylak DP / 2004 / Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer / N Engl J Med 351:1513~1520
de Bono JS / 2010 / Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : a randomised open-label trial / Lancet 376:1147~1154
Scher HI / 2012 / Increased survival with enzalutamide in prostate cancer after chemotherapy / N Engl J Med 367:1187~1197
Tannock IF / 2004 / Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer / N Engl J Med 351:1502~1512
Petrylak DP / 2004 / Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer / N Engl J Med 351:1513~1520
de Bono JS / 2010 / Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : a randomised open-label trial / Lancet 376:1147~1154
Scher HI / 2012 / Increased survival with enzalutamide in prostate cancer after chemotherapy / N Engl J Med 367:1187~1197
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Analyses of Multiple Factors for Determination of "Selected Patients" Who Should Receive Rechallenge Treatment in Metastatic Colorectal Cancer: a Retrospective Study from Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
Cancer Research and Treatment
2018 .01
-
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
Yonsei Medical Journal
2023 .02
-
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
Cancer Research and Treatment
2016 .01
-
Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
Cancer Research and Treatment
2015 .01
-
Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
Cancer Research and Treatment
2018 .01
-
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
Cancer Research and Treatment
2016 .01
-
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
Investigative and Clinical Urology
2019 .01
-
Docetaxel-Aggravated Psoriasis
Annals of Dermatology
2019 .01
-
The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
Tuberculosis and Respiratory Diseases
2019 .01
-
Lung Cancer in Women, a Different Disease: Survival Differences by Sex in Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
전립선암의 호르몬 및 항암화학요법
대한의사협회지
2015 .01
-
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
Cancer Research and Treatment
2019 .01
-
Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Cancer Research and Treatment
2022 .10
-
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer
Cancer Research and Treatment
2022 .04
-
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
Cancer Research and Treatment
2016 .01
-
Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study
Gut and Liver
2024 .07
-
Secondary Primary Prostate Cancer after Colorectal Cancer: A Nationwide Population-based Cohort Study in Korea
대한암예방학회지
2017 .01
-
Analysis on Breast Cancer Refractory to Neoadjuvant Docetaxel Chemotherapy Following Adriamycin and Cyclophosphamide
대한외과학회 학술대회 초록집
2020 .11
-
The association of family history of prostate cancer with the diagnosis of clinically significant prostate cancer in Korean population
Investigative and Clinical Urology
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0